Researcher Database


Freeword

YUASA Hiroaki

FacultyGraduate School of Pharmaceutical Sciences Department of Biopharmaceutics
PositionProfessor
Mail
HomepageURLhttp://www.phar.nagoya-cu.ac.jp/hp/yzg/e-index.html
Birthday
Last Updated :2020/07/02

Researcher Profile and Settings

Education

  •   1985  - 1986 , The University of Tokyo, Graduate School of Pharmaceutical Sciences
  •   1983  - 1985 , The University of Tokyo, Graduate School of Pharmaceutical Sciences
  •   1979  - 1983 , The University of Tokyo, Faculty of Pharmaceutical Sciences (completed)

Degree

  • Ph.D., The University of Tokyo

Association Memberships

  • American Society for Pharmacology and Experimental Therapeutics
  • International Society for the Study of Xenobiotics
  • International Pharmaceutical Federation
  • Controlled Release Society
  • American Association of Pharmaceutifical Scientists
  • Academy of Pharmaceutical Science and Technology, Japan
  • Japanese Society for the Study of Xenobiotics
  • Pharmaceutical Society of Japan

Academic & Professional Experience

  •   2002  - 現在, Nagoya City University, Graduate School of Pharmaceutical Sciences, Professor
  •   2000  - 2002 , Nagoya City University, Faculty of Pharmaceutical Sciences, Professor
  •   1992  - 2000 , Nagoya City University, Faculty of Pharmaceutical Sciences, Associate Professor
  •   1991  - 1992 , Nagoya City University, Faculty of Pharmaceutical Sciences, Senior Assistant Professor
  •   1989  - 1991 , The University of Michigan, College of Pharmacy, Postdoctoral Fellow
  •   1986  - 1991 , Nagoya City University, Faculty of Pharmaceutical Sciences, Assistant Professor

Research Activities

Research Areas

  • Life sciences, Clinical pharmacy, Biopharmaceutics (drug diposition studies)

Research Interests

    drug therapy, transporter, drug disposition, drug development

Published Papers

  • Identification of the amino acid residue responsible for the myricetin sensitivity of human proton-coupled folate transporter., Yamashiro T, Yasujima T, Ohta K, Inoue K, Yuasa H, Scientific reports, 9, (1) , 12 , Refereed
  • Organic anion transporter 1 (OAT1/SLC22A6) enhances bioluminescence based on d-luciferin-luciferase reaction in living cells by facilitating the intracellular accumulation of d-luciferin., Furuya T, Takehara I, Shimura A, Kishimoto H, Yasujima T, Ohta K, Shirasaka Y, Yuasa H, Inoue K, Biochemical and biophysical research communications, 495, (3) 2152 - 2157, Refereed
  • Urate transport function of rat sodium-dependent nucleobase transporter 1., Yasujima T, Murata C, Mimura Y, Murata T, Ohkubo M, Ohta K, Inoue K, Yuasa H, Physiological reports, 6, (10) , Refereed
  • Specific inhibitory effects of myricetin on human proton-coupled folate transporter: Comparison with its effects on rat proton-coupled folate transporter and human riboflavin transporter 3., Yamashiro T, Yasujima T, Ohta K, Inoue K, Yuasa H, Drug metabolism and pharmacokinetics, 32, (6) 311 - 314, Refereed
  • Functional identification of organic cation transporter 1 as an atenolol transporter sensitive to flavonoids., Mimura Y, Yasujima T, Ohta K, Inoue K, Yuasa H, Biochemistry and biophysics reports, 2, 166 - 171, Refereed
  • Transcriptional regulation of PCFT by KLF4, HNF4 alpha, CDX2 and C/EBP alpha: Implication in its site-specific expression in the small intestine, Mai Furumiya, Katsuhisa Inoue, Kinya Ohta, Yayoi Hayashi, Hiroaki Yuasa, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 431, (2) 158 - 163, 02 , Refereed, Proton-coupled folate transporter (PCFT), which is responsible for the intestinal uptake of folates and analogs, is expressed only in the proximal region in the small intestine. The present study was to examine its transcriptional regulation, which may be involved in such a unique expression profile and potentially in its alteration, using dual-luciferase reporter assays in human embryonic kidney (HEK) 293 cells. The luciferase activity derived from the reporter construct containing the 5'-flanking sequence of -1695/+96 of the human PCFT gene was enhanced most extensively by the introduction of Kruppel-like factor 4 (KLF4). The KLF4-induced luciferase activity was further enhanced by hepatocyte nuclear factor 4 alpha (HNF4 alpha) synergistically. To the contrary, caudal-type homeobox transcription factor 2 (CDX2) and CCAAT/enhancer-binding protein alpha (C/EBP alpha) extensively suppressed the luciferase activity induced by KLF4 alone and also that induced by KLF4 and HNF4 alpha. Western blot analysis using the rat small intestine indicated uniform expression of KLF4 along the intestinal tract, proximal-oriented expression of HNF4 alpha, distal-oriented expression of CDX2 and C/EBP alpha. These results suggest that the activity of PCFT promoter is basically induced by KLF4 and the gradiented expression profile of PCFT may be at least in part accounted for by those of HNF4 alpha, CDX2 and C/EBP alpha. (C) 2013 Elsevier Inc. All rights reserved.
  • Nicotinate Uptake by Two Kinetically Distinct Na+-Dependent Carrier-Mediated Transport Systems in the Rat Small Intestine, Masahiko Ohkubo, Kinya Ohta, Katsuhisa Inoue, Hiroaki Yuasa, DRUG METABOLISM AND PHARMACOKINETICS, 27, (2) 255 - 262, 04 , Refereed, Recent studies have identified monocarboxylate transporter 1 (MCT1), sodium-coupled monocarboxylate transporter 1 (SMCT1) and SMCT2 as those that may be involved in the carrier-mediated intestinal absorption of nicotinate, but their roles have not been fully clarified yet. To address the issue, we examined the uptake of nicotinate in the rat small intestine by using everted tissue sacs. The uptake of nicotinate was Na+-dependent and saturable at pH 7.4 in both the jejunum and ileum. The saturable transport consisted of a single component with the Michaelis constant (K-m) of 1.18mM in the jejunum, while in the ileum it consisted of the high and the low affinity components with the K-m values of 8.62 mu M and 2.36 mM, respectively, and the latter was prevailing in transport capacity and similar to the jejunal transport component. Nicotinate uptake activity attributable to a H+-dependent transporter like MCT1 was, however, only minimal in the two intestinal sites. These results suggest that a low affinity type of SMCT2-like transporter would be in operation with high capacity throughout the small intestine, playing the role as the major intestinal nicotinate uptake transporter, and a high affinity type of SMCT1-like transporter would be additionally in operation in the ileum.
  • Functional characteristics of two human MATE transporters: kinetics of cimetidine transport and profiles of inhibition by various compounds., Ohta KY, Inoue K, Yasujima T, Ishimaru M, Yuasa H, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 12, (3) 388 - 396, Refereed

Misc

  • 【ビタミン この古くて新しき世界】 水溶性ビタミン類の腸管吸収に関わるトランスポーター群, 湯浅 博昭, ファルマシア, 51, (3) 201 - 205,   2015 03
  • 【トランスポーターと疾患研究の最前線】 薬剤応答性とトランスポーター メトトレキサートによる関節リウマチ治療と葉酸トランスポーター, 井上 勝央, 湯浅 博昭, 医学のあゆみ, 245, (1) 127 - 132,   2013 04
  • 【消化管の輸送体】 核酸輸送体, 井上 勝央, 湯浅 博昭, G.I.Research, 19, (5) 426 - 432,   2011 10
  • 【ビタミン・バイオファクターのトランスポーター】 PCFT/SLC46A1による葉酸の吸収機構, 井上 勝央, 湯浅 博昭, ビタミン, 84, (10) 472 - 479,   2010 10
  • アドメノート 薬物体内動態に関わるトランスポーターと臨床的諸問題(第1回) トランスポーター研究の動向2010, 湯浅 博昭, Drug Metabolism and Pharmacokinetics, 25, (4) 6 - 11,   2010 08
  • 【薬物投与の基礎と臨床】 薬物の腸管吸収におけるトランスポーターの役割 ペプチドトランスポーターによるβ-ラクタム系抗生物質の吸収を中心として, 湯浅 博昭, 医学のあゆみ, 197, (1) 3 - 7,   2001 04

Books etc

  • Drug absorption from the colon in situ, Hiroaki Yuasa, "Drug Absorption Studies: In Situ, In Vitro and In Silico Models" ed. by Carsten Ehrhardt and Kwang-Jin Kim, Springer, New York, NY, pp. 77 - 88 (Ch. 3),   2008
  • 消化管吸収の評価法, 湯浅 博昭, 「分子薬物動態学」,杉山 雄一,楠原 洋之編,南山堂,東京,pp. 447 - 459(第24章),   2008
  • 消化管吸収性の予測:in vitroからin vivoへ, 湯浅 博昭, 「薬物バイオアベイラビリティ評価と改善の科学:より良き医薬品開発のために」,杉山 雄一編,現代医療社,東京,pp. 229 - 245(第7章,第1部),   1998
  • 腸管吸収の予測:in vitroからin vivoへ, 湯浅 博昭, 「ファーマコキネティクス研究の方法と技術」,日本薬物動態学会ワークショップ実行委員会編,日本薬物動態学会,東京,pp. 169 - 181(第8章),   1993
  • 薬物生体膜輸送のヒトへの外挿, 湯浅 博昭, 「続医薬品の開発(第4巻):薬物の生体膜輸送と組織標的化II」,寺田 弘,辻 彰編,廣川書店,東京,pp. 518 - 523(第5章,第8節),   1991

Patents

  • 小腸上皮細胞特異的な尿酸トランスポーター及びその利用, 湯浅 博昭, 保嶋 智也, 井上 勝央, 山本 俊輔, 特願2017-152034

Awards & Honors

  •   1995 , Japanese Society for the Study of Xenobiotics, Young Investigator Award
  •   1993 , Pharmaceutical Society of Japan (Tokai Chapter), Young Investigator Award

Research Grants & Projects

  • アクアポリン10の核酸塩基輸送機能:核酸塩基及び関連薬物の小腸吸収における役割, 科学研究費, 基盤研究C,   2013  - 2015
  • 樹状細胞に高発現する小胞体膜局在性トランスポーターの機能と免疫系における役割, 科学研究費, 挑戦的萌芽研究,   2011  - 2012
  • HCT-15細胞型Na+依存性グリセロールトランスポーターの同定と輸送機能解明, 科学研究費, 基盤研究C,   2008  - 2010
  • HCT-15細胞モデルにおけるグリセロールトランスポーターの分子的実体と輸送機能, 科学研究費, 基盤研究C,   2006  - 2007
  • 腸管でのグリセロール吸収を担う新規トランスポーターの機能と生理的役割, 科学研究費, 基盤研究C,   2004  - 2005
  • 結腸の吸収機能の薬物動態学的及び細胞生物学的解析:経口徐放剤設計の最適化のために, 科学研究費, 基盤研究C,   2000  - 2002
  • 経口薬物吸収の生理機構論的解析, 科学研究費, 奨励研究A,   1994  - 1994


Copyright (c) MEDIA FUSION Co.,Ltd. All rights reserved.